Oncolytic DNA hairpin pairs (oHPs) are introduced to the cancer cell. When the oHPs encounter the tumor-causing overexpressed microRNA (miRNA), they unravel to connect with the miRNA and each other to form longer DNA strands. These elongated strands then trigger an immune response, the body’s built-in defense mechanism, which inhibits further tumor growth.
CREDIT: 2022 Akimitsu Okamoto
Hairpin-shaped DNA binds with microRNA in cancer cells to trigger an immune response
Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way. The method was effective in lab tests against human cervical cancer- and breast cancer-derived cells, and against malignant melanoma cells from mice. The team created a pair of chemically synthesized, hairpin-shaped, cancer-killing DNA. When the DNA pairs were injected into cancer cells, they connected to microRNA (miRNA) molecules that are overproduced in certain cancers. Once connected to the miRNA, they unraveled and joined together, forming longer chains of DNA which triggered an immune response. This response not only killed the cancer cells but prevented further growth of cancerous tissue. This method is different from conventional anticancer drug treatments and is hoped to bring about a new era of drug development.
Cancer is a sadly familiar global health concern and current methods of treatment have their limitations. However, drugs based on nucleic acids — namely DNA and RNA, the vital information-carrying molecules — can control the biological functions of cells, and are expected to transform the future of medicine and provide a significant boost towards efforts to overcome cancer and other hard-to-treat illnesses, caused by viruses and genetic diseases.
A research group at the University of Tokyo, led by Assistant Professor Kunihiko Morihiro and Professor Akimitsu Okamoto from the Graduate School of Engineering, were inspired to create a new anticancer drug using artificial DNA. “We thought that if we can create new drugs that work by a different mechanism of action from that of conventional drugs, they may be effective against cancers that have been untreatable up to now,” said Okamoto.
Nucleic acid drug use for cancer treatment has been challenging because it is difficult to make the nucleic acids distinguish between cancer cells and other healthy cells. This means there is a risk of adversely affecting the patient’s immune system if healthy cells are inadvertently attacked. However, for the first time, the team was able to develop a hairpin-shaped DNA strand that can activate a natural immune response to target and kill specific cancerous cells.
Cancer cells can overexpress, or make too many copies of, certain DNA or RNA molecules, causing them to not function normally. The team created artificial oncolytic (cancer-killing) hairpin DNA pairs called oHPs. These oHPs were triggered to form longer DNA strands when they encountered a short (micro) RNA called miR-21, which is overexpressed in some cancers. Typically, oHPs don’t form longer strands due to their curved hairpin shape. However, when the artificial oHPs enter a cell and encounter the target microRNA, they open up to combine with it and form a longer strand. This then causes the immune system to recognize the presence of the overexpressed miR-21 as dangerous and activate an innate immune response, which ultimately leads to the death of the cancer cells.
The tests were effective against overexpressed miR-21 found in human cervical cancer-derived cells, human triple-negative breast cancer-derived cells, and mouse malignant melanoma-derived cells. “The formation of long DNA strands due to the interaction between short DNA oHPs and overexpressed miR-21, found by this research group, is the first example of its use as a selective immune amplification response which can target tumor regression, providing a new class of nucleic acid drug candidates with a mechanism that is completely different from known nucleic acid drugs,” said Okamoto.
“The results of this study are good news for doctors, drug discovery researchers and cancer patients, as we believe it will give them new options for drug development and medication policies. Next, we will aim for drug discovery based on the results of this research, and examine in detail the drug efficacy, toxicity and potential administration methods.” This research still has many steps to go before a treatment can be made available, but the team is confident in the benefits of nucleic acids for new drug discovery.
Original Article: Artificial DNA kills cancer
More from: University of Tokyo
The Latest Updates from Bing News
Go deeper with Bing News on:
- We're Halfway to Creating Fully Artificial Living Yeast Cells
The geneticists at InGen pulled off a scientific magic trick when they created the first dinosaurs at Jurassic Park. The actual process is almost certainly too complicated to fully explain onscreen ...
- Yeast with 50% synthetic DNA engineered in breakthrough genetic studies
Scientists have hit a major milestone in a 15-year project trying to build a completely synthetic yeast genome. Reporting in a bumper crop of new papers, the team has engineered viable yeast cells ...
- Ovarian cancer: Artificial intelligence predicts therapy responses
A model based on artificial intelligence is able to predict the therapy outcome (measured by volumetric reduction of tumor lesions) in 80% of ovarian cancer patients. The AI-based model has an ...
- Scientists created the first yeast with artificial DNA
Scientists have finally managed to create the first synthetic yeast chromosomes, but keeping them together is a lot harder.
- Scientists build yeast with artificial DNA in a major synthetic biology advance
For more than 15 years, scientists have worked to build a complex cell with an entire genome built from scratch. This week they announced they've reached a major milestone: They've created synthetic ...
Go deeper with Bing News on:
- With advanced cancer, Ottawa's Sindy Hooper is racing to find a way into a U.S. clinical trial
Ottawa’s Sindy Hooper is in a new, desperate race. An accomplished Ironman competitor and triathlete, Hooper, 60, is now living with terminal (stage ...
- 'I would swim 150 lengths a week, but breast cancer drug was so brutal I had to be helped off the sofa': Why you should think twice before taking miracle pill
This 4p-a-day pill has been hailed as a game-changer. But the frequent side effects mean women are already giving it up in their droves.
- Strictly's Dianne Buswell shares emotional message from dad as he undergoes chemotherapy
Strictly Come Dancing star Dianne Buswell has received a very sweet good luck message from her dad Mark, ahead of the Blackpool special of the BBC series. This comes after the 34- ...
- Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Comprehensive Insights on More than 180 Companies and 290+ Pipeline Dugs - ResearchAndMarkets.com
The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 180+ companies and 290+ drugs ...
- Scientists uncover "genomic tug of war" that influences chemotherapy's effectiveness
Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's ...